Halozyme Therapeutics Inc. (HALO)

16.01
NASDAQ : Health Technology
Prev Close 16.48
Day Low/High 15.89 / 16.53
52 Wk Low/High 13.24 / 18.85
Avg Volume 860.20K
Exchange NASDAQ
Shares Outstanding 146.31M
Market Cap 2.41B
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

(Photo: Business Wire)

(Photo: Business Wire)

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that it is launching XES Sensual, the first sexual wellness system with an integrated applicator, specifically designed to deliver a cannabidiol...

(Photo: Business Wire)

(Photo: Business Wire)

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that it is launching XES Sensual, the first sexual wellness system with an integrated applicator, specifically designed to deliver a cannabidiol...

Halozyme Reports Second Quarter 2019 Results

Halozyme Reports Second Quarter 2019 Results

- Total Revenues Increase 11% to $39.1 Million Compared to $35.2 Million in Prior-year Period -

Halozyme To Participate In 39th Annual Canaccord Genuity Growth Conference

Halozyme To Participate In 39th Annual Canaccord Genuity Growth Conference

SAN DIEGO, July 25, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the 39th Annual Canaccord Genuity Growth Conference in Boston, MA.

Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call

Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call

SAN DIEGO, July 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the second quarter 2019 on Tuesday,...

(Photo: Business Wire)

(Photo: Business Wire)

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that it has launched the Shatterizer™, the first custom vaporizer device made for the DabTab™ Dablets™ allowing consumers to experience smooth,...

Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology

Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology

SAN DIEGO, July 19, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Janssen-Cilag International NV (Janssen) has submitted an extension...

Halozyme Announces First Clinical Dosing In Argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology

Halozyme Announces First Clinical Dosing In Argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology

SAN DIEGO, July 17, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has dosed the first subject in a phase 1 clinical trial...

Halo Announces Lease Buy Down Of Its California Facilities

Halo Announces Lease Buy Down Of Its California Facilities

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that it has entered into an agreement with Falcon International ("Falcon") to buy out the entire rental premium of its California locations at...

Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology

Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology

SAN DIEGO, July 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that its collaborator Janssen Biotech, Inc.

Halozyme Announces CRADA With National Institute Of Allergy And Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology

Halozyme Announces CRADA With National Institute Of Allergy And Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology

- NIAID to Study Use of ENHANZE® Technology with Broadly Neutralizing Antibodies for Development of New HIV Treatments -

REPEAT/Ms. Louisa Mojela To Speak On Social Justice And Environmental Sustainability At Parliament Of The United Kingdom On June 24, 2019

REPEAT/Ms. Louisa Mojela To Speak On Social Justice And Environmental Sustainability At Parliament Of The United Kingdom On June 24, 2019

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that Ms.

Ms. Louisa Mojela To Speak On Social Justice And Environmental Sustainability At Parliament Of The United Kingdom On June 24, 2019

Ms. Louisa Mojela To Speak On Social Justice And Environmental Sustainability At Parliament Of The United Kingdom On June 24, 2019

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that Ms.

REPEAT/Lesotho Deputy Prime Minister, Mr. Monyane Moleleki, To Join Halo And Ms. Mojela At European Cannabis Week

REPEAT/Lesotho Deputy Prime Minister, Mr. Monyane Moleleki, To Join Halo And Ms. Mojela At European Cannabis Week

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that the Deputy Prime Minister of Lesotho, Mr.

Lesotho Deputy Prime Minister, Mr. Monyane Moleleki, To Join Halo And Ms. Mojela At European Cannabis Week

Lesotho Deputy Prime Minister, Mr. Monyane Moleleki, To Join Halo And Ms. Mojela At European Cannabis Week

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that the Deputy Prime Minister of Lesotho, Mr.

REPEAT/Halo Labs Intends To Appoint Ms. Louisa Mojela As Chairman Of The Board Upon Closing Of Bophelo Bioscience Acquisition

REPEAT/Halo Labs Intends To Appoint Ms. Louisa Mojela As Chairman Of The Board Upon Closing Of Bophelo Bioscience Acquisition

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that upon closing of the previously announced acquisition of Bophelo Bioscience & Wellness (Pty) Ltd.

Halo Labs Intends To Appoint Ms. Louisa Mojela As Chairman Of The Board Upon Closing Of Bophelo Bioscience Acquisition

Halo Labs Intends To Appoint Ms. Louisa Mojela As Chairman Of The Board Upon Closing Of Bophelo Bioscience Acquisition

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that upon closing of the previously announced acquisition of Bophelo Bioscience & Wellness (Pty) Ltd.

REPEAT/ Halo Labs To Expand Globally And Acquire Bophelo Bioscience

REPEAT/ Halo Labs To Expand Globally And Acquire Bophelo Bioscience

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that it has entered into a non-binding letter of intent (LOI) for the proposed acquisition of Bophelo Bioscience & Wellness (Pty) Ltd ("Bophelo") (the...

Halo Labs To Expand Globally And Acquire Bophelo Bioscience

Halo Labs To Expand Globally And Acquire Bophelo Bioscience

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that it has entered into a non-binding letter of intent (LOI) for the proposed acquisition of Bophelo Bioscience & Wellness (Pty) Ltd ("Bophelo") (the...

Halozyme To Participate In Upcoming Investor Conferences

Halozyme To Participate In Upcoming Investor Conferences

SAN DIEGO, June 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in two upcoming investor conferences.

REPEAT/Halo Labs Products Now Available Via Online Marketplace Eaze In California And Oregon

REPEAT/Halo Labs Products Now Available Via Online Marketplace Eaze In California And Oregon

Halo Labs Inc. ("Halo" or the "Company") (NEO:HALO, OTCQX:AGEEF, Germany:A9KN) is pleased to announce their launch on the leading online cannabis marketplace Eaze to sell it products direct to consumers in California and Oregon.

Halo Labs Products Now Available Via Online Marketplace Eaze In California And Oregon

Halo Labs Products Now Available Via Online Marketplace Eaze In California And Oregon

Halo Labs Inc. ("Halo" or the "Company") (NEO:HALO, OTCQX:AGEEF, Germany:A9KN) is pleased to announce their launch on the leading online cannabis marketplace Eaze to sell it products direct to consumers in California and Oregon.

Halozyme Announces Argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement

Halozyme Announces Argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement

- Triggers $10 million milestone payment to Halozyme in the second quarter -

Halo Labs Announces Conversion Of Debentures Into Common Shares

Halo Labs Announces Conversion Of Debentures Into Common Shares

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) provides an update on recent conversions of the Company's 8% unsecured convertible debentures (the "Debentures").

Halozyme To Participate In Bank Of America Merrill Lynch Health Care Conference 2019

Halozyme To Participate In Bank Of America Merrill Lynch Health Care Conference 2019

SAN DIEGO, May 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the Bank of America Merrill Lynch Health Care Conference 2019 in Las...

Halo To Present At The 2019 Cannabis Conference Hosted By Canaccord Genuity In NYC On May 14th

Halo To Present At The 2019 Cannabis Conference Hosted By Canaccord Genuity In NYC On May 14th

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) today announces that Kiran Sidhu will present at the 2019 Cannabis Conference Hosted by Canaccord Genuity at the Grand Hyatt New York in New York, NY on May 14 th, 2019 at...

Halozyme Reports First Quarter 2019 Results

Halozyme Reports First Quarter 2019 Results

- Revenue of $56.9 Million Compared to $30.9 Million in Prior-year Period -

Halo Labs Retracts Statement Regarding April Revenue; Reviewing Disclosure Approach

Halo Labs Retracts Statement Regarding April Revenue; Reviewing Disclosure Approach

Halo Labs Inc . ("Halo" or the "Company") (NEO:HALO, OTCQX:AGEEF, Germany:A9KN) retracts its press release dated May 3, 2019 wherein it disclosed estimated revenues for the month of April 2019.

TheStreet Quant Rating: D (Sell)